Ezetimibe and Testosterone Interaction

Avoid
Mechanism-based 75% confidence

Ezetimibe and Testosterone have a potentially harmful interaction with 75% confidence. Both Ezetimibe and Testosterone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the heart, so monitoring these systems is recommended.

Compound Profiles

Ezetimibe

Cholesterol Absorption Inhibitor | Lipid Management On Cycle

Ezetimibe selectively inhibits the NPC1L1 transporter protein located on the luminal surface of enterocytes in the jejunum of the small intestine. NPC1L1 is the critical gateway for intestinal cholesterol absorption, responsible for uptaking both dietary cholesterol and the much larger pool of biliary cholesterol that is recirculated through the enterohepatic cycle.

Half-life: ~22 hours Typical dose: 10 mg/day cardiovascular
npc1l1 hepatotoxiclipid disruptingteratogenic
View full profile

Testosterone

Anabolic-Androgenic Steroid | Primary Male Sex Hormone

Testosterone exerts its effects primarily through binding to the intracellular androgen receptor (AR), forming a hormone-receptor complex that translocates to the nucleus and modulates gene transcription. This drives protein synthesis in skeletal muscle (anabolic effect), stimulates erythropoietin production in the kidneys to increase red blood cell mass, promotes osteoblast activity and bone mineral density, and regulates libido and cognitive function.

Half-life: ~8 days (cypionate) Typical dose: 100-200 mg/week (TRT) anabolic, sexual health, metabolic
5 alpha reductaseandrogen receptoraromataseepo receptor androgeniccarcinogenic riskestrogenichematocrit raising
View full profile

Combined Organ Load

Heart
moderate
Gonads
moderate
Liver
low
Pancreas
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Ezetimibe, Testosterone). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds disrupt lipids (Ezetimibe, Testosterone). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (Ezetimibe, Testosterone). Monitor accordingly.

Frequently Asked Questions

Can I take Ezetimibe with Testosterone?

Combining Ezetimibe with Testosterone is not recommended. Both Ezetimibe and Testosterone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Ezetimibe and Testosterone safe together?

This combination carries significant risk. Both Ezetimibe and Testosterone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Ezetimibe and Testosterone?

Both Ezetimibe and Testosterone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 75% confidence and is inferred from pharmacological mechanism analysis.

How should I time Ezetimibe and Testosterone?

Ezetimibe has a half-life of ~22 hours and Testosterone has a half-life of ~8 days (cypionate). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Ezetimibe vs Testosterone

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.